Form 8-K uniQure N.V. For: Jun 17

Go back to Form 8-K uniQure N.V. For: Jun 17

Mizuho on uniQure BV (QURE): 'expressed confidence the overall signal — namely the slowing of disease progression — should remain directionally consistent'

June 17, 2026 1:27 PM EDT

Mizuho analyst Uy Ear reiterated an Outperform rating and $35.00 price target on uniQure BV (NASDAQ: QURE).

The analyst comments "FDA Under New Leadership Seems to Signal Renewed Flexibility in Rare Diseases: Regarding the Type B meeting, management noted the core review team remained largely unchanged, but leadership-level discussions seem to have enabled a more pragmatic path forward, which led to the agency's willingness to find the 3-year Phase I/II results as supportive of an Accelerated BLA filing and non-sham control confirmatory Phase 3 trial. Management highlighted a constructive shift in tone following recent... More

uniQure BV (QURE) PT Raised to $71 at Stifel

June 17, 2026 9:31 AM EDT

Stifel analyst Paul Matteis raised the price target on uniQure BV (NASDAQ: QURE) to $71.00 (from $28.00) while maintaining a Buy rating.

The analyst comments "We're reiterating our Buy rating on QURE and raising our TP to $71, on the back of a positive and welcome surprise around FDA's ~180 on the regulatory path for AMT-130 (LINK). Bottom line: we now model a slightly greater than 50%... More